Syllabus for the Future of Digital Medicine course, 2023- Biology, Genetics, Technology and BioInformatics. Includes lectures from Noam Shomron, Michal Rosen-Zvi, Eyal Zimlichman, Gila Tolub, Dana Bar-On, Yesha Sivan, Vladi Dvoryis, Varda Shalev, Avi Schroeder, Christian Tidano, Eyal Toledano.
Running head COURSE PROJECT- ROUGH DRAFT .docxsusanschei
Running head: COURSE PROJECT- ROUGH DRAFT 1
Course Project- Rough Draft
Weltee Wolo
Rasmussen College
Author Note
This paper is being submitted on November 24, 2016, for Mischelle Pittman Henry’s
H400/HSA4191 Healthcare Information System course
COURSE PROJECT- ROUGH DRAFT
2
Technology has become very useful in many sectors. In the health care industry, it has
changed the way health care services are provided. It turns out to be a critical tool for
competition in the health care market. Quality has now been at the forefront when it comes to
shaping any health care program (Feenberg, 2012). This makes health care institutions to strive
and produces better services to its customers.
A look at surgical procedures together with state of the art proper care method, an
important position from the infirmary is represented by the technology. Compared to the past,
health care institutions have now been successful when it comes to performing a number of
lifetime harmful and critical surgical procedures (Mali, 2012). All these are attributed to
advanced models to be used in surgeries brought about by technology. There is much equipment
that has been brought about by technology advancement including 3D echocardiogram and CT
reconstruction. These two have made surgery more efficient by improving imaging capabilities
which enable surgeons to operate without hindrances on the human body (Raza, Sabik, Masabni,
Ainkaran, Lytle, W. B., & Blackstone, 2014). Healthcare services have improved too, by the
introduction of robotic surgery and teleconferencing. The latter has enabled doctors to provide
knowledge and expertise far and wide irrespective of their physical location. They can monitor,
track and communicate with their patients to help them keeping tabs on their ailments (Raza, et
al., 2014). Robotic surgery helps doctors conduct surgery remotely with the use of a machine that
can multitask and overcome some of the limitations a human doctor may have. This improves the
likelihood of an operation to be successful which benefits both the physician and the patient.
Additionally, there are Pc Served Medical procedures together with CAS, which have
been termed as computer or laptop well guided medical procedures. Most surgeons, especially
cosmetic surgeons rely on these procedures in some surgery activities on various subjects, such
COURSE PROJECT- ROUGH DRAFT
3
as orthopedic and otolaryngologic operations (Hendricks-Munoz, 2015). In clinical laboratories,
well-trained individuals are making use ...
Talk entitled "from the Virtual Human to a Digital Me" presented at the Virtual Physiological Human 2012 Conference held at IET Savoy, Savoy Place, London, 18-20 September 2012.
Dr. Dennis Wang discusses possible ways to enable ML methods to be more powerful for discovery and to reduce ambiguity within translational medicine, allowing data-informed decision-making to deliver the next generation of diagnostics and therapeutics to patients quicker, at lowered costs, and at scale.
The talk by Dr. Dennis Wang was followed by a panel discussion with Mr. Albert Wang, M. Eng., Head, IT Business Partner, Translational Research & Technologies, Bristol-Myers Squibb.
Running head COURSE PROJECT- ROUGH DRAFT .docxsusanschei
Running head: COURSE PROJECT- ROUGH DRAFT 1
Course Project- Rough Draft
Weltee Wolo
Rasmussen College
Author Note
This paper is being submitted on November 24, 2016, for Mischelle Pittman Henry’s
H400/HSA4191 Healthcare Information System course
COURSE PROJECT- ROUGH DRAFT
2
Technology has become very useful in many sectors. In the health care industry, it has
changed the way health care services are provided. It turns out to be a critical tool for
competition in the health care market. Quality has now been at the forefront when it comes to
shaping any health care program (Feenberg, 2012). This makes health care institutions to strive
and produces better services to its customers.
A look at surgical procedures together with state of the art proper care method, an
important position from the infirmary is represented by the technology. Compared to the past,
health care institutions have now been successful when it comes to performing a number of
lifetime harmful and critical surgical procedures (Mali, 2012). All these are attributed to
advanced models to be used in surgeries brought about by technology. There is much equipment
that has been brought about by technology advancement including 3D echocardiogram and CT
reconstruction. These two have made surgery more efficient by improving imaging capabilities
which enable surgeons to operate without hindrances on the human body (Raza, Sabik, Masabni,
Ainkaran, Lytle, W. B., & Blackstone, 2014). Healthcare services have improved too, by the
introduction of robotic surgery and teleconferencing. The latter has enabled doctors to provide
knowledge and expertise far and wide irrespective of their physical location. They can monitor,
track and communicate with their patients to help them keeping tabs on their ailments (Raza, et
al., 2014). Robotic surgery helps doctors conduct surgery remotely with the use of a machine that
can multitask and overcome some of the limitations a human doctor may have. This improves the
likelihood of an operation to be successful which benefits both the physician and the patient.
Additionally, there are Pc Served Medical procedures together with CAS, which have
been termed as computer or laptop well guided medical procedures. Most surgeons, especially
cosmetic surgeons rely on these procedures in some surgery activities on various subjects, such
COURSE PROJECT- ROUGH DRAFT
3
as orthopedic and otolaryngologic operations (Hendricks-Munoz, 2015). In clinical laboratories,
well-trained individuals are making use ...
Talk entitled "from the Virtual Human to a Digital Me" presented at the Virtual Physiological Human 2012 Conference held at IET Savoy, Savoy Place, London, 18-20 September 2012.
Dr. Dennis Wang discusses possible ways to enable ML methods to be more powerful for discovery and to reduce ambiguity within translational medicine, allowing data-informed decision-making to deliver the next generation of diagnostics and therapeutics to patients quicker, at lowered costs, and at scale.
The talk by Dr. Dennis Wang was followed by a panel discussion with Mr. Albert Wang, M. Eng., Head, IT Business Partner, Translational Research & Technologies, Bristol-Myers Squibb.
Welcome to the age of cognitive computing: where intelligent machines have
moved from the realms of science fiction to the present day. This groundbreaking
technology is driving advanced discoveries and allowing improved decision-making –
resulting in better patient care
Strengthening Health Systems through the application of Wireless TechnologyOPS Colombia
Presentación realizada por el Dr. Trishan Panch, de Harvard School of Public Health, el 20 de Septiembre en OPS Colombia, en el espacio de intercambio sobre e-health.
El Dr. Panch, participa, con el auspicio de esta Representación, como conferencista en el IV Congreso Colombiano de Bioingeniería e Ingeniería Biomédica que se realizará en Barranquilla del 21 al 24 de septiembre del 2011.
Precision and Participatory Medicine - Medinfo 2015 Panel on big data. Includes the proposal to use the term Expotype to characterise the Exposome of an individual. Electronic expo typing would refer to the automatic construction of individual expo types from electronic clinical records and other sources of environmental risk factor and exposure data.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
Healthcare Innovation Technology Group MeetingDavid Voran
Presentation to a Kansas City Healthcare Innovation Technology Group Meeting on June 28, 2011.
Describes Innovation processes, needs, some examples and advice for those creating innovative technology products to be used in Healthcare.
Data-integration platform for cancer research:cBioPortal demoCORBEL
Participants will be introduced to the data-integration platform cBioPortal. Here, different sources of research data (clinical, imaging, biosample and experimental) of a study are integrated, enabling viewing, querying and analysis.
This webinar is aimed at data managers, researchers, PhD students and postdocs involved in clinical, translational and biomedical research.
Improvements in sequencing technologies have led to a deluge of genomics data in many fields of research. Specifically, the increasing size of cancer-related genomics datasets require comprehensive software solutions that remain accessible to clinical researchers. Clearly, there is an obvious need for tools that integrate genomics and other molecular biology results with the phenotypic and clinical outcome data. During this webinar, the cBio Cancer Genomics Portal (cBioPortal) will be introduced through a practical use case.
The cBioPortal is an open source data integration platform that enables researchers to view, query, analyse and share complex genomic cancer datasets in a user-friendly manner. The platform was originally developed by Memorial Sloan Kettering Cancer Center (New York, USA)1 and is actively maintained and further developed by an international community. The original instance of cBioPortal (http://cbioportal.org) currently provides access to data from almost 83000 tumor samples from 273 public studies.
The demo will include:
· short introduction on the FAIR principles (Findable, Accessible, Interoperable, Reusable)
· navigation through a public study on the data-integration platform cBioPortal
· recreation of select plots from publications of interest using cBioPortal functionalities
The CORBEL webinar series aims to address challenges and share best practice between biological and medical research infrastructures. The series is aimed at technical operators of RIs and is aligned with the CORBEL competency framework.
ADAPTIVE LEARNING EXPERT SYSTEM FOR DIAGNOSIS AND MANAGEMENT OF VIRAL HEPATITISijaia
Viral hepatitis is the regularly found health problem throughout the world among other easily transmitted
diseases, such as tuberculosis, human immune virus, malaria and so on. Among all hepatitis viruses, the
uppermost numbers of deaths are result from the long-lasting hepatitis C infection or long-lasting hepatitis
B. In order to develop this system, the knowledge is acquired using both structured and semi-structured
interviews from internists of St.Paul Hospital. Once the knowledge is acquired, it is modeled and
represented using rule based reasoning techniques. Both forward and backward chaining is used to infer
the rules and provide appropriate advices in the developed expert system. For the purpose of developing
the prototype expert system SWI-prolog editor also used. The proposed system has the ability to adapt with
dynamic knowledge by generalizing rules and discover new rules through learning the newly arrived
knowledge from domain experts adaptively without any help from the knowledge engineer.
Adaptive Learning Expert System for Diagnosis and Management of Viral Hepatitisgerogepatton
Viral hepatitis is the regularly found health problem throughout the world among other easily transmitted diseases, such as tuberculosis, human immune virus, malaria and so on. Among all hepatitis viruses, the uppermost numbers of deaths are result from the long-lasting hepatitis C infection or long-lasting hepatitis B. In order to develop this system, the knowledge is acquired using both structured and semi-structured interviews from internists of St.Paul Hospital. Once the knowledge is acquired, it is modeled and represented using rule based reasoning techniques. Both forward and backward chaining is used to infer the rules and provide appropriate advices in the developed expert system. For the purpose of developing the prototype expert system SWI-prolog editor also used. The proposed system has the ability to adapt with dynamic knowledge by generalizing rules and discover new rules through learning the newly arrived knowledge from domain experts adaptively without any help from the knowledge engineer
Why Precision Medicine and Personalized Healthcare and Why Now? Links to Canada’s Rare Disease Strategy The Future is Now
1) Marc LePage, Genome Canada
2) Michael Duong, Roche
3) Danica Stanimirovic, National Research Council
4) Daniel Gaudet, University of Montreal
5) Christine Dalgleish, Patient Perspective
6) Jamie Bruce, Khure Health
The Future of mHealth - Jay Srini - March 2011LifeWIRE Corp
Jay Srini's presentation of her take on the Future of mHealth, presented at the 3rd mHealth Networking Conference, March 30, 2011. Aside from being one of the preeminent thought leader in the area of innovation and mhealth, she holds a number of positions including Assistant Professor at the University of Pittsburgh and CIO for LifeWIRE Corp.
An Introduction to Bioinformatics
Drexel University INFO648-900-200915
A Presentation of Health Informatics Group 5
Cecilia Vernes
Joel Abueg
Kadodjomon Yeo
Sharon McDowell Hall
Terrence Hughes
Companies, organizations, and research institutes that are committed to bettering the lives of living organisms fall under the umbrella term known as the life sciences industry. Pharmaceuticals, biotechnology, environmental sciences, biomedicine, nutraceuticals, neurology, cell biology, biophysics, and a lot of other subfields might be classified as some of the different subfields that fall under the umbrella of the life sciences business.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
More Related Content
Similar to Course Syllabus (Digital Rosh): The Future of Digital Medicine- Biology, Genetics, Technology & BioInformatics
Welcome to the age of cognitive computing: where intelligent machines have
moved from the realms of science fiction to the present day. This groundbreaking
technology is driving advanced discoveries and allowing improved decision-making –
resulting in better patient care
Strengthening Health Systems through the application of Wireless TechnologyOPS Colombia
Presentación realizada por el Dr. Trishan Panch, de Harvard School of Public Health, el 20 de Septiembre en OPS Colombia, en el espacio de intercambio sobre e-health.
El Dr. Panch, participa, con el auspicio de esta Representación, como conferencista en el IV Congreso Colombiano de Bioingeniería e Ingeniería Biomédica que se realizará en Barranquilla del 21 al 24 de septiembre del 2011.
Precision and Participatory Medicine - Medinfo 2015 Panel on big data. Includes the proposal to use the term Expotype to characterise the Exposome of an individual. Electronic expo typing would refer to the automatic construction of individual expo types from electronic clinical records and other sources of environmental risk factor and exposure data.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
Healthcare Innovation Technology Group MeetingDavid Voran
Presentation to a Kansas City Healthcare Innovation Technology Group Meeting on June 28, 2011.
Describes Innovation processes, needs, some examples and advice for those creating innovative technology products to be used in Healthcare.
Data-integration platform for cancer research:cBioPortal demoCORBEL
Participants will be introduced to the data-integration platform cBioPortal. Here, different sources of research data (clinical, imaging, biosample and experimental) of a study are integrated, enabling viewing, querying and analysis.
This webinar is aimed at data managers, researchers, PhD students and postdocs involved in clinical, translational and biomedical research.
Improvements in sequencing technologies have led to a deluge of genomics data in many fields of research. Specifically, the increasing size of cancer-related genomics datasets require comprehensive software solutions that remain accessible to clinical researchers. Clearly, there is an obvious need for tools that integrate genomics and other molecular biology results with the phenotypic and clinical outcome data. During this webinar, the cBio Cancer Genomics Portal (cBioPortal) will be introduced through a practical use case.
The cBioPortal is an open source data integration platform that enables researchers to view, query, analyse and share complex genomic cancer datasets in a user-friendly manner. The platform was originally developed by Memorial Sloan Kettering Cancer Center (New York, USA)1 and is actively maintained and further developed by an international community. The original instance of cBioPortal (http://cbioportal.org) currently provides access to data from almost 83000 tumor samples from 273 public studies.
The demo will include:
· short introduction on the FAIR principles (Findable, Accessible, Interoperable, Reusable)
· navigation through a public study on the data-integration platform cBioPortal
· recreation of select plots from publications of interest using cBioPortal functionalities
The CORBEL webinar series aims to address challenges and share best practice between biological and medical research infrastructures. The series is aimed at technical operators of RIs and is aligned with the CORBEL competency framework.
ADAPTIVE LEARNING EXPERT SYSTEM FOR DIAGNOSIS AND MANAGEMENT OF VIRAL HEPATITISijaia
Viral hepatitis is the regularly found health problem throughout the world among other easily transmitted
diseases, such as tuberculosis, human immune virus, malaria and so on. Among all hepatitis viruses, the
uppermost numbers of deaths are result from the long-lasting hepatitis C infection or long-lasting hepatitis
B. In order to develop this system, the knowledge is acquired using both structured and semi-structured
interviews from internists of St.Paul Hospital. Once the knowledge is acquired, it is modeled and
represented using rule based reasoning techniques. Both forward and backward chaining is used to infer
the rules and provide appropriate advices in the developed expert system. For the purpose of developing
the prototype expert system SWI-prolog editor also used. The proposed system has the ability to adapt with
dynamic knowledge by generalizing rules and discover new rules through learning the newly arrived
knowledge from domain experts adaptively without any help from the knowledge engineer.
Adaptive Learning Expert System for Diagnosis and Management of Viral Hepatitisgerogepatton
Viral hepatitis is the regularly found health problem throughout the world among other easily transmitted diseases, such as tuberculosis, human immune virus, malaria and so on. Among all hepatitis viruses, the uppermost numbers of deaths are result from the long-lasting hepatitis C infection or long-lasting hepatitis B. In order to develop this system, the knowledge is acquired using both structured and semi-structured interviews from internists of St.Paul Hospital. Once the knowledge is acquired, it is modeled and represented using rule based reasoning techniques. Both forward and backward chaining is used to infer the rules and provide appropriate advices in the developed expert system. For the purpose of developing the prototype expert system SWI-prolog editor also used. The proposed system has the ability to adapt with dynamic knowledge by generalizing rules and discover new rules through learning the newly arrived knowledge from domain experts adaptively without any help from the knowledge engineer
Why Precision Medicine and Personalized Healthcare and Why Now? Links to Canada’s Rare Disease Strategy The Future is Now
1) Marc LePage, Genome Canada
2) Michael Duong, Roche
3) Danica Stanimirovic, National Research Council
4) Daniel Gaudet, University of Montreal
5) Christine Dalgleish, Patient Perspective
6) Jamie Bruce, Khure Health
The Future of mHealth - Jay Srini - March 2011LifeWIRE Corp
Jay Srini's presentation of her take on the Future of mHealth, presented at the 3rd mHealth Networking Conference, March 30, 2011. Aside from being one of the preeminent thought leader in the area of innovation and mhealth, she holds a number of positions including Assistant Professor at the University of Pittsburgh and CIO for LifeWIRE Corp.
An Introduction to Bioinformatics
Drexel University INFO648-900-200915
A Presentation of Health Informatics Group 5
Cecilia Vernes
Joel Abueg
Kadodjomon Yeo
Sharon McDowell Hall
Terrence Hughes
Companies, organizations, and research institutes that are committed to bettering the lives of living organisms fall under the umbrella term known as the life sciences industry. Pharmaceuticals, biotechnology, environmental sciences, biomedicine, nutraceuticals, neurology, cell biology, biophysics, and a lot of other subfields might be classified as some of the different subfields that fall under the umbrella of the life sciences business.
Similar to Course Syllabus (Digital Rosh): The Future of Digital Medicine- Biology, Genetics, Technology & BioInformatics (20)
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
mHealth Israel_Healthcare Finance and M&A- What Comes NextLevi Shapiro
Healthcare Finance and M&A, What Comes Next? Presentation by Matthew R. Kittay, National Co-Chair, M&A Practice Group, Fox Rothschild LLP. Includes fundraising and investments. Breakouts by subsector- Healthcare (overall), Healthcare services, Digital health, Biopharma, Pharmatech, Medtech, Healthcare IT. Healthcare transaction distribution breakouts. Exits remain flat. Avoiding common legal pitfalls like IP, compliance, governance structure. Current legislation in health law. IP strategy for healthtech.
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...Levi Shapiro
Oppenheimer & Co. Inc, co-Head of Healthcare Investment Banking, Michael Margolis, provides H1 Healthcare Financing, Funding and M&A Overview. Table of Contents
1. Broader Market Overview
2. Biotech M&A Market Overview
3. Private Biotech Financing Market Update
4. Key Advice For Healthcare Companies
Current State of Play; Healthcare has Underperformed the Broader Market Over the Last Twelve Months; Signal-to-Noise is Getting Worse; Healthcare IPO Activity has Decreased Significantly Since 20–21 Pandemic Levels; Biotech Financing Activity Has Remained Robust in 2024; Biotech M&A Market Remains Incredibly Active; Biotech M&A Market Remains Incredibly Active; Big Pharma Upcoming Patent Expirations; Since November 2023 Oncology has accounted for over half of all M&A; Oncology, Autoimmune / I&I, and CV & Metabolic Remain the Top Areas in M&A; Small Molecule Beats Out All Other Modalities in M&A Despite IRA Concerns; Value of Big Pharma Acquisitions by Therapeutic Area in Q1 2024; Private Financing Market Update; 2024 Private Placement Activity On Track to Approach, If Not Exceed, 2020 Levels; Oncology, Particularly Solid Tumor, Continues to Attract VC Investors; Despite the IRA, Small Molecules Continue to Attract VC Dollars; Preclinical-Stage Companies Make Up Almost Half of Private Placements in 2023; Valuations by Development Stage – 2023; Typical Biotech Investors Remained Active in Q1 2024; 23 $100M+ Deals were Raised in Q1 2024; Biotech Fundraising Momentum Continued into 2024; Key Advice For Israeli Healthcare Companies; Although Israel has Strong Presence on US Public Markets, There is Room to Grow; Telling Your Story Effectively; Interacting with Investors to Build Long-term Credibility; Seven Simple Rules for Pitch Decks;
Version Bravo- The Springboard for Navy SEAL entrepreneurship, cohort 003Levi Shapiro
Description of the Version Bravo intensive entrepreneurial launch program for 7 Israeli and 7 US former Navy SEALs. Details about each startup concept, the CEOs, the sector, etc.
Radical Life Extension_Dr. Leon Peshkin_Dec 2023Levi Shapiro
Presentation for mHealth Israel by Dr. Leon Peshkin, Harvard Medical School, exploring research into Embryology and Longevity, emphasizing Germline and protein aggregates. Includes current overview, anti aging through history, Lifespan Expansion, ALEC: Animal Life Expectancy in Controls, Scalable Platform in Pharmacobiology, Embryos Cleanse Protein Aggregates, Lysosomal switch triggers proteostasis renewal, Xenopus, Rejuvenation Roadmap, Citizen Science Approach to Aging, Xenopus: Maternal Dowry Molecules, Human Disease Modeling
Israel’s Life Science Hub 2023 English Abstract.pdfLevi Shapiro
The war between Israel and Hamas brings its own set of business
challenges. Challenges that may impact how we communicate with
partners and investors abroad. We should portray the life science sector as resilient and adaptable, even in times of crisis. This document is a a messaging outline for Israel's Life Science Hub despite the war with Hamas. Four key points to emphasize:
1) Global activity (resilience and agility)
2) Continuity of care and preventive medicine
3) World leading clinical trials industry
4) Dynamic scientific, research and entrepreneurial ecosystems
Gil Bashe FINN Partners: The Future of Digital Health – Nose Dive or Transfor...Levi Shapiro
The Future of Digital Health – Nose Dive or Transformation, by Gil Bashe, Dec 4th, 2023 at the mHealth Israel conference. Digital Health Innovation Ecosystem Investment Trends. Data & Methodology. Digital Health Taxonomy. Key Insights for Digital Health Innovation in H1 2023. Global Digital Health Funding Across Regions. Funding in North America. Shifting Focus in North America Digital Health Funding. Investment Focus for Digital Health Venture Funding. Ventures are turning to partnerships for proof points, scale and funding. 2022 new partnerships. North America digital health investor participation. Most active partners in North America. North America Ecosystem Development. Venture distribution by stage. Funding distribution. Comparison to 2022 Funding. Noteworthy deals, noteworthy exits.
Urgent Request and Call for Action for Ensuring Safety and Inclusivity at MITLevi Shapiro
We, 465 MIT Alumni, Staff, and Students, are writing to express our deep concern, fear, and disappointment regarding the recent protest that took place Thursday afternoon, in front of the MIT Stratton Student Center. While we fully support the principles of free
speech and the right to peaceful assembly, it is essential that we also prioritize the safety and well-being of all members of the MIT
community.
During the protest, a particular slogan was prominently displayed and chanted, which has raised significant concerns. The slogan
"From the [Jordan] river to the [Mediterranean] sea, Palestine will be free!" has been a source of contention due to its potential
implications and the real safety risks it poses to Jewish and Israeli students on campus [See video footage attached]. This slogan
has been time and again associated with calls for the destruction of the State of Israel and has been used in contexts that
promote violence, which raises legitimate concerns about the safety and security of our Jewish and Israeli students and staff.
Furthermore, we would like to draw your attention to recent events that demonstrate the potential dangers associated with this
slogan. During the 2023 Israel-Hamas war, British Home Secretary Suella Braverman proposed criminalizing the use of the slogan
in certain contexts, recognizing the potential harm it can cause. Additionally, on October 11, ‘23, Vienna police banned a
demonstration, citing the inclusion of the phrase "from the river to the sea" in invitations, as it was seen as a portrayal of a violation
of Article 2 of the European Convention on Human Rights.
In addition to the use of these derogatory messages, several attendees of the event used hateful wordings and messages towards
Jewish and Israeli bystanders. In one case, a perpetrator aggressively held their bicycles as intended to harm a Jewish MIT student,
stating that “[your] ancestors did not die in the Holocaust so they could kill Palestinians” [See video footage attached]. In another
incident, protesters chanted “one solution, intifada revolution”. In the context of the on-going Israeli-Palestinian conflict, the word
"Intifada" means the armed and violent Palestinian insurrection targeting Israelis, including civilians, which resulted in the killing of
thousands of Israelis in the last few decades.
On Oct. 22nd, a statement by MIT CAA (Coalition Against Apartheid) came to our attention. In this document, MIT CCA states that
they "hold the Israeli regime responsible for all unfolding violence". They later call the October 7th terror attack a "response to
the settler colonial regime", and continue justifying it throughout the document.
In this matter, MIT CAA is justifying the heinous and barbaric crimes committed on Oct 7th. Furthermore, these statements have the
potential to fuel acts of aggression
Overview of the Israeli exhibitors at the 2023 HLTH conference in Las Vegas. Exhibitors included 6Degrees, AppScent, Belong.Life, Datos, Expecting, IntraPosition, Kahun Medical, Kemtai, Maverick, Neteera, QuantaIX, Respiration Scan, Nerivio, Xoltar.
40% of Israeli technology investment is devoted to Life Science. Within that domain, the largest sector is Medical Devices and Digital Health (over 65 percent of companies). In the medical device arena, Israeli scientists and engineers have integrated advanced technologies in electronics, communications and electro-optics to develop world-class innovations in Digital Imaging, Medical Lasers, Telemedicine, Early Diagnostics,
Smart Surgical Equipment and more. Over 600 medical device exporters engaged in a variety of medical application
such as Cardiovascular and Peripheral Vascular, Neurology and Degenerative Diseases, Preparedness and Emergency
Medicine, Intensive Care, Women Health, Orthopedics and Sport Medicine, Gastrointestinal, Infection Control, Ophthalmology, Pain and Wound Management, Oral and Dental Care, Dermatology and Aesthetics
Baptist Health- Engineering the Future of HealthcareLevi Shapiro
Presentation by Mark Coticchia, Chief Innovation Officer, Baptist Health, for mHealth Israel community, September, 2023. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences.
A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies.Innovation is paramount to health system’s performance and reputation.
Becker’s 2019 Advisory Board survey revealed innovation and technology ranked as the top priority among healthcare finance professionals - up from eighth in 2018. 90% healthcare/life science leaders agree that the pandemic will fundamentally change the way they do business, requiring new products, services, processes, and business models (McKinsey: Innovation Through Crisis Survey). Innovation has been proven to help health systems in many ways. A capability and culture of innovation accomplish numerous goals:
Innovation capability and culture improve the care and work environment. They enhance the reputation through recognition for discoveries made at and through Baptist Health. They aid in the recruitment and retention of top talent. And they help systems harness money that otherwise would be leaving the system – licensing revenues and investment returns and corporate research support and donor revenues. Successful Programs - Common Underpinnings. Innovation as a strategic, institutional priority
Program built on institutional assets and centers of excellence
Experienced, professional team
Technology development and sourcing, Dedicated, long term support. Doing healthcare innovation well at a large enterprise takes a highly specialized team and skill set. Collectively, they need to have deep knowledge of healthcare regulation, medical procedures, patient safety, business development, transactions, business law, innovation markets, entrepreneurship, venture capital, commercialization, tech transfer, organizational change management, and much more. Programs- services, technology management, corporate co-creation, global medical service lines and facilities; Focus on market opportunity vs. technology; Select & concentrate on winners; Operate as a business; Proactive in new company formation; Progress, milestones, preliminary results; Building New Innovation Pathways; Improving Treatment for Cancer Patients; Predicting & Preventing Heart Attacks; Improving Outcomes in Cardiac Care; Enhancing a Culture of Innovation at Baptist Health & South Florida; Cleerly, TriVentures, COTA; Innovation is paramount to health system’s performance and reputation.
Baptist Health has established an innovation function predicated on best practices and tailored to its assets and the opportunities extending from Miami’s economic growth
YEDA Techn Transfer at Weizmann Institute- Discord and Challenges in Academic...Levi Shapiro
Presentation by Yael Klionsky, YEDA, for the mHealth Israel community in September, 2023. Title: Challenges in Academic Technology Transfer. Examples-
Transplantation Immunology and Immunometabolism. Efranat Pharma was developing an anticancer immunotherapy treatment based on a natural plasma protein molecule. From target discovery to clinical validation. Clinical-stage drug discovery and development company utilizing a broadly applicable, predictive
computational discovery platforms to identify novel drug targets and new biological pathways and develop
therapeutics in the field of cancer immunotherapy. To allow SOCIETY to benefit from discoveries made at the academic institution. To enable SCIENTISTS to transfer their new technologies to the market. To create an additional source of INCOME for the INSTITUTE so that more independent research can be conducted. Three important elements that make an idea patentable:
1) The invention must be new: the same idea can’t have been
published before in any form; 2) There must be some inventive step of ‘non-obviousness’.
This can be hard to define and depends on the context; 3) The disclosure in a patent must be sufficient for a skilled
person to reproduce the invention with only routine effort; Technology Transfer Company - modus operandi; OUR PURPOSE- To provoke transformative scientific breakthroughs that will shape the future of humanity; SCIENTIFIC STAFF- 300 Principal investigators, >2,000 Research students and PhDs; 5 FACULTIES – BASIC SCIENCE, Biology, Physics, Biochemistry, Math/CS
Chemistry; Generated IP- 57% in Life Science & Biotech; Among the Highest
Income per Researcher
Worldwide; 1959 (First TTO outside the US); Today- More applications per PI than in most Ivy league universities; Copaxone- >$30B
ANNUAL SALES BASED ON Weizmann IP; 20 new licenses per year and 10 new companies per annum; www.yedarnd.com
HADASIT: Tech Transfer and More in Life ScienceLevi Shapiro
Overview of activities in Life Science of Hadasit, the technology transfer arm of Hadassah Hospital in Jerusalem. Includes details about Jerusalem Biodesign program; spinouts like Brainwatch; details about tech transfer (the Secret Engine Behind Israel’s Success); relationship and examples of TTOs enabling Israel's greatest success stories; contrasting of Adademia (Scientific driven research, Creation of new knowledge, Publication, Sharing of Material, Social responsibilities) and Industry (Applied research & specific objectives, Develop new products, Product development, Secrecy and patent protection, Organization responsibilities); Development gap between initial inventions and product development; the Art of translation (from academic research to medical companies); Tech transfer transforms cutting-edge research into marketable healthcare technologies; LICENSING TO EXISTING COMPANIES; SPINNING OFF STARTUPS; CO-DEVELOPMENT OF JOINT IP; Technology Transfer Offices from Academia/Research Hospitals – to Industry; Overview of Hadassah and Hadasit (TECHNOLOGY TRANSFER COMPANY AND INNOVATION ENGINE OF HADASSAH UNIVERSITY HOSPITALS); Examples of “HADASSAH MADE” PRODUCTS IN THE GLOBAL MARKET; RECENT TECH TRANSFER SUCCESS; Example- Lineage Exclusive Worldwide Collaboration with Genentech Opregen® RPE Cell Therapy for the Treatment of Ocular Disorders; HADASIT PILLARS-
NURTURING INTERNAL INNOVATION, Tech Transfer, EXTERNAL INNOVATION. External- SERVICES & COLLABORATIONS WITH COMPANIES, BIOHOUSE FOR STARTUPS, DIGITAL HEALTH ACCELERATOR); Internal Innovation- NURTURING INTERNAL INNOVATION, HADASSAH SEED FUND, JERUSALEM BIODESIGN PROGRAM; TYPES OF RELATIONS WITH EXTERNAL COMPANIES- CONSULTING, SAB, CLINICAL TRIALS, R&D SERVICES, DATA LICENCE, ALPHA/BETA SITE, PILOTS, DESIGN PARTNERSHIPS.
Presenting to Investors & the Media.pdfLevi Shapiro
Presenting to Investors and the Media, lecture by Drew Levinson, LifeSci Communications to mHealth Israel. Three sections: Making a good presentation, Handling
interviews with reporters and Answers that resonate. PRESENTING TO INVESTORS AND THE MEDIA- Compelling delivery, Commanding a room, • Lasting Impact. A good presentation includes Information, Motivation and Excitement. Never put them to sleep. Audience impact includes content, credibility and delivery. Decisions are made leading to potential partnerships, winning business, so much more than a deck, your business, your brand, you. How to captivate begins with storytelling and conversation. More than features- benefits, humanize, positive impact. Don't complicate your message with jargon. Feel the passion- contagious, vision, determination. Know your audience- who are they, what do they know about you, how much do they know, interests, concerns. Articulate your vision- see it, feel it, believe in it. Take them on your journey- compelling narrative, make it personal, why are you doing this, inspiration. Your team- experienced, knowledgeable, aligned, execute. Risks and challenges- recognize, address, plan to mitigate. Test drive your room. What does it look like? Where is the podium? Where will I be standing? Where will you be sitting? Feel comfortable. Three parts to attention. The beginning- attention, interest, what's in it for them, entusiasm, preview. The middle- core, insights, challenges, solutions, relatable. The ending- summary, reinforce, messages, benefits, call to action, keep the momentum going. How to answer questions. The Four R's: repeat, reinforce, refer, remember. Talking to reporters- necessity; Good interview can enhance reputation; Bad interview can tarnish reputation; Preparation is vital. Shapes public opinion: Elevates your brand; Establishes authority; Showcases your business; A bridge; Reputation; Trust; Visibility. Know the reporter. Audience; What have they written; Previous stories; Questions asked. Concise- clear, succinct, engaging. Make it relatable: Stories; Anecdotes; Experiences; Examples; Metaphors; Connect. Honesty and transparency. It is okay not to know every answer. You don’t have to answer every question. Control the narrative. What not to do when talking to reporters. Come up with another way to say no comment. What to wear- solid colors, blues and grays, nothing distracting. Expertise, passion, vision, lasting impression, connections. High stakes, high rewards. Preparation; Know your audience; Deliver with confidence; Enthusiasm; Authenticity. Begin the journey. Engage in dialogue; Build relationships; Inspire trust and confidence; Valued; Enlightened; Motivated and excited.
Nissan Elimelech, Founder, Augmedics: How I Built the World's First XR Surgic...Levi Shapiro
Presentation by Nissan Elimelech, Founder, Augmedics: How I Built the World's First XR Surgical Navigation Company and What's Next for XR. Covers the company founding across multiple milestones and key success factors.
Beyeonics CEO, Ron Schneider, Advances in Medical XRLevi Shapiro
Overview by Beyeonics CEO, Ron Schneider, about the company. Beyeonics One is the first ophthalmic exoscope with an augmented reality surgical headset. It is a high-definition, fully digital imaging platform enabling surgeons to see a magnified, three-dimensional (3D) image of the surgical field. The small footprint, the fast setup, automation, and zero turnover time between procedures all contribute to the efficiency operating rooms strive for. Over 3000 cases to date. Unconstrained Movement. Unconstrained workflow. Data connectivity. Designed for continuous innovation.
XRHealth is revolutionizing healthcare, bringing patient care into the Metaverse. Includes a description of the TeleHealth Platform. Lessons Learned – Building the clinical Metaverse. Last mile delivery
Building a product in the Metaverse is easy – getting people to use it is hard. Virtual Care can’t be based only on XR. HMDs bring friction – Charging, Guardian, Safety, Passwords etc. Expanding virtually in a brick & mortar payer environment. Once you cross the chasm – adherence/ satisfaction/retention goes ballistic. Patient Outcomes-
Patients report significant improvement in symptoms following treatment. Adherence - patients follow Home Exercise Plans as prescribed. 92.2% with XRHealth vs 50% with regular treatment. Patient satisfaction - 85 NPS vs 38 NPS in healthcare
93.3% patient retention -complete treatment cycle as prescribed. XRHealth Luna AI Reduces Hot Flashes and Improves Psychological Well-Being in Women with Breast and Ovarian Cancer: A Pilot Study. Virtual reality immersion compared to monitored anesthesia care for hand surgery: A randomized controlled trial. Lessons Learned – Autism Spectrum Disorder. The future of the Mediverse.
Digital Health in US Health Systems.pptxLevi Shapiro
April, 2023 presentation by Gil Bashe, Global Chair, Health Practice, FINN Partners. Insights and analytics, in collaboration with Galen Growth, tracking Digital Health collaboration, adoption, integration, and best practices across the leading US Health Systems. There is a section about focus areas for digital health in health systems and hospitals. The most active health systems are partnering more in diagnosis and have a higher share of digital tools for research. Comprehensive breakout of digital health activities at the Top 10 players: Mayo, Mount Sinai, Cleveland Clinic, Sloan Kettering, Massachusetts General, Northwell, Cedars Sinai, Brigham & Women's, InterMountain. Global breakout of health systems with digital health partnerships at scale. Geographical breakout of digital health partner headquarters (by region). Strong preference for B2B business model. 1/3 of digital health partnerships with Early Stage venture companies. Emphasis is on strong clinical evidence. Portfolio size allows greater diversity. Cluster distribution depends on therapeutic area. Digital health analytics breakout including alpha score, venture similarity score, venture valuation, team signal, partnership signal, evidence signal.
Alagene BioFoundry: Releasing the Genie Out of the Bottle Levi Shapiro
Overview of Israel's leading BioFoundry, Alagene by Roni Cohen, CEO. Overview of Synthetic Biology- Taking biology into engineering mode. Using synthetic genes, to program cells to become factories to make devices, sensors, pharmaceuticals, renewable chemicals, fuels and food. Alagene has four partners with complementary expertise. Hylabs is an established and experienced, highly regulated service company. Reichman University is an academic partner with a commercialization mindset. The Israel Innovation Authority is the government and Aleph VC is an investment firm. Alagene is a home for innovation and R&D center in SynBio, serving as a one-stop—shop for knowledge, methods, and instrumentation to enable our customers in Israel and worldwide to get to their proof of concept. Alagene is anend to end Infrastructure supporting gene & host optimization in microbial systems. The infrastructure enables two Major Implementations- Biomanufacturing and Direct Microbial Application. One example is the development of a Dairy Milk Producing System, using Genetic Optimization and Process Optimization and Validation. Finally, Alagene shared the following recent project examples: Computational prediction for introducing new genes into microbes; Precision fermentation for yeast producing dairy proteins; Bio production of psychoactive / cannabinoid molecule in yeast; Bio production of growth factors for the cultured meat industry; Developing new inhouse tools to support strain optimization; Bio production of egg protein; Computational modeling of full metabolic network in Algae; Bio production of rare sugars with a low glycemic index.
Digital Health Ecosystem- 2022 3rd Quarter ReportLevi Shapiro
Snapshot of the global digital health investment and innovation landscape, Q3 2022, prepared by FINN Partners and Galen Growth. Includes digital health funding history, 2021 digital health investment funding breakouts, winners and losers in 2022 digital health venture funding, global vernture disribution by therapeutic area, venture distribution by stage, regulatory filings by digital health area, change in venture funding by therapeutic area, global digital health funding across regions, top funded therapeutic areas, venture funding in key digital health innovation clusters and geographies, digital health funding across regions, 2022 digital health in Israel, QoQ digital health funding by region, QoQ digital health funding, five year trended digital health funding across regions, noteworthy exits in MENA, M&A, Medigate, Breezometer, AIDOC, Vayyar, Viz.ai, Cathworks, Hello Heart, Israel venture funding and exits
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Best Ayurvedic medicine for Gas and IndigestionSwastikAyurveda
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Course Syllabus (Digital Rosh): The Future of Digital Medicine- Biology, Genetics, Technology & BioInformatics
1. DLC844066: The Future of Digital Medicine - Theory to Practice Page 1 of 15
In the third decade of the 21st century, healthcare is extensively digital. The
COVID-19 pandemic further accelerated the adoption of digital technologies by
the medical sector. At the same time, state-of-the-art digital tools helped
humanity overcome the pandemic and speed-up vaccine and drug development
processes. This course is an introduction to the exciting field of digital medicine
with a special focus on genetics and their applications.
DLC844066: The Future of Digital Medicine is designed for healthcare
stakeholders who see the opportunities of the digital era together with facing its
challenges. The course is a theoretical and practical introduction to digital
medicine with an emphasis on genomics. It is specially built for healthcare
specialists, researchers, healthcare managers, and policymakers willing to learn
how they can harness digital technologies and data science to develop the future
of medicine.
The course consists of 10 weekly sessions to be held on Mondays. Each session
lasts 3 hours (17:00-20:00 IDT / 15:00-18:00 UTC / 10:00-13:00 EST) via Zoom.
The sessions combine theory, practice, and peer learning.
All the course’s material, including the recorded sessions, additional theory items,
case studies, and more will be available for the course participants 24/7 on
DigitalRosh online platform.
This is an introductory course, but it requires basic knowledge of digital
technology and the healthcare domain. An interview with the course manager is
a prerequisite to joining the course.
2. DLC844066: The Future of Digital Medicine - Theory to Practice Page 2 of 15
In This Document:
In This Document: 2
About Digital Medicine 3
About This Course 3
Faculty and Team 4
Industry Speakers 5
Outline of the meetings 7
Session 1: The Context 7
Session 2: Biology 7
Session 3: Genetics 8
Session 4: DNA 8
Session 5: RNA and More 9
Session 6: Technology 9
Session 7: Research 10
Session 8: Bioinformatics and Systems 11
Session 9: Applications 11
Session 10: Management 12
More Details and Registration 13
Appendix 1: The World of Digital Medicine on DigitalRosh 15
Appendix 2: Testimonials of Previous Courses’ Participants 16
Participants of DigitalRosh courses say:
“You never stop learning digital, certainly when you meet people from different disciplines.
The biggest thing for me is the peer learning that opened my mind completely.”
Tony Cohen, CEO, of Maccabi Dent
“The course is organized excellently. The schedule is kept religiously and the time is fully
exploited. Everything is digital and available any time - real LLL”
Yarden Yardeni, Project manager, ministry of justice
3. DLC844066: The Future of Digital Medicine - Theory to Practice Page 3 of 15
About Digital Medicine
From hybrid healthcare platforms and at-home diagnostic devices, through AI-driven
diagnosis and robotic surgery, and all the way to microfluidic “organs-on-a-chip”,
3D-printed tissues, genomics, and individual therapeutics, digital technology
revolutionizes medicine, improves diagnostic and therapeutic precision, enhances the
ability to overcome once incurable diseases, and improves the overall quality of life.
Digital medicine can be defined as data-driven diagnosis and treatment of health
conditions. While computers have been used in medicine for almost half a century,
digital medicine does not aim to deal with hardware per se - it is increasingly a field
dominated by sophisticated software gathering large amounts of evidence, structuring
them into data, and analyzing the data to provide personalized insights and therapeutic
intervention.
The amount of data received from living organisms grow exponentially, and its
continuous second-to-second flow is enormous - making it readable only by
sophisticated algorithms. These serve us in developing new medical technologies -
however, unlike digital health or digital wellness applications, digital medicine should be
ethical and supported by a sound body of scientific evidence.
About This Course
This course will provide a birds-eye overview of digital medicine before delving
into one of its most promising fields - genomic and personalized medicine.
This is an evolving and exciting scientific domain, aimed at providing every individual
with customized treatment based not only on his/her own genetic code but also on the
epigenetic factors regulating the expression of particular genes. The course will include
an introduction to genetics and the expression of genes in an organism, together with
technologies for genome sequencing and analysis and furthermore, methods for
meaningful analysis of the extracted data. Finally, we will discuss how genomic
medicine is brought from the lab to the clinic today, as well as future treatment
modalities stemming from it.
The topics discussed in the course will include:
● Genetics - DNA sequencing, how data is gathered and accumulated; as well as
somatic and cancerous changes, mutations, and rare diseases. We will also
learn about cell-free DNA, gene expression, non-coding RNA, and methylation.
● Technology - current technologies, their applications and limitations, the
products already in the market, and in late-stage development.
● Bioinformatics - how data can be integrated into systems biology, and what new
techniques are used today to collect, gather and interpret data.
4. DLC844066: The Future of Digital Medicine - Theory to Practice Page 4 of 15
Faculty and Team
The course is led by Prof. Noam Shomron, head of the Functional
Genomics Laboratory at Tel Aviv University’s School of Medicine.
He is also head of the Rare Genomics Institute - Israel, the
Djerassi Institute of Oncology, and a team at the Tel Aviv University
Innovation Labs (TILabs).
Prof. Shomron received his Bachelor's degree in Biotechnology at
Macquarie University in Sydney, Australia; his Master's degree in
Gene Therapy at the Hebrew University of Jerusalem; and his
graduate studies in Genetics at Tel Aviv University where he
worked on regulatory RNA systems. As a Post-Doctorate affiliate
at MIT in Cambridge, USA, Noam gained expertise in combining high-throughput data
with computational analysis in order to decipher gene regulation in health and disease.
Shomron is also the co-founder of several biotech companies.
The course is operated by DigitalRosh. Based in Tel Aviv, Israel,
DigitalRosh is a professional LLL (lifelong learning) platform
catering to digital leaders in Israel and abroad. DigitalRosh is led
by Prof. Yesha Sivan, founder, and CEO of i8 Ventures
(http://i8.ventures) and an experienced advisor, researcher, and
academic. He is also an MBA visiting professor focusing on digital,
innovation, and venture at the Technion – Israel Institute of
Technology. Prof. Sivan’s professional experience includes
developing and deploying innovative solutions for corporate,
hi-tech, government, and defense environments.
The course is managed by Dr. Vladi Dvoyris, Director of Digital
Health Programs at DigitalRosh. A DMD (Hebrew University) and
MBA (Technion - Israel Institute of Technology) graduate, a
practicing clinician in the field of dental implantology, and an
evangelist of digital healthcare, Dr. Dvoyris combines hands-on
clinical experience with a thorough understanding of information
technology and an insightful approach towards healthcare delivery
and management in the digital world.
5. DLC844066: The Future of Digital Medicine - Theory to Practice Page 5 of 15
Industry Speakers
The course will include guest lectures by leaders of data-driven medicine, who will
share their hands-on experience from the field. The guest speakers in the course are:
Prof. Avi Schroeder - Head of the Targeted Drug Delivery
and Personalized Medicine Group at the Faculty of Chemical
Engineering, Technion - Israel Institute of Technology.
Dr. Michal Rosen-Zvi - Director, AI for Accelerated
Healthcare & Life Sciences Discovery at IBM Research and a
Professor at the Faculty of Medicine at the Hebrew University
of Jerusalem.
Prof. Varda Shalev - Co-Founder and Chief Medical Officer
at Alike.Health; Managing Partner at Team8.
Dr. Eyal Zimlichman - Deputy Director General; Chief
Medical Officer; and Chief Innovation and Commercialization
Officer at Sheba Medical Center (selected as one of the
Top-10 hospitals in the world by Newsweek).
6. DLC844066: The Future of Digital Medicine - Theory to Practice Page 6 of 15
Dr. Dana Bar-On - Senior Director, Head of Academic Affairs
and Networks, Specialty R&D at Teva Pharmaceuticals.
Dr. Christian Tidona - Founder and General Manager,
BioMed X Institute
Mr. Eyal Toledano - Co-Founder and former CTO of Zebra
Medical Vision. Co-Founder, stealth startup.
Ms. Gila Tolub - Partner at McKinsey, leading the Israeli
chapter of McKinsey’s global health technology network.
7. DLC844066: The Future of Digital Medicine - Theory to Practice Page 7 of 15
Outline of the meetings
Session 1: The Context
When: Monday, 1-MAY-2023 17:00-20:00 IDT • 10:00-13:00 EST
Theory 1 Theory 2
Explanation of the big picture.
The coil example.
The AGI Elephant - Prof. Yesha Sivan
Practice
Introduction to the course participants - getting to know each other.
Details
In this session we will explore the basic units of living organisms, the cells, their content, and
how they transfer information from generation to generation. How does a cell grow, divide,
differentiate, and specialize? What are genes and what information do they carry?
● The cell, organs, the body
● DNA, RNA, proteins
● Systems and complexity
● What might go wrong
Session 2: Biology
When: Monday, 8-MAY-2023 17:00-20:00 IDT • 10:00-13:00 EST
Theory Practice
Types of genetics and epigenetics. Group discussion:
Discuss the complexity of identifying changes
in genetics and epigenetics, how they would
affect physical health, and what ways might be
used to resolve or consolidate these multiple
layers?
Multiple choice quiz - Basic Biological
Concepts
Details
In this session we will understand how genetic inheritance works, how epigenetics influence
and intervene with our genetic fate, and how all these interact in complex systems. We will
also look at where genomics might go wrong and how the body deals with these changes.
● Genetics and inheritance
● Epigenetic mechanisms
● Systems and complexity
● What might go wrong
8. DLC844066: The Future of Digital Medicine - Theory to Practice Page 8 of 15
Session 3: Genetics
When: Monday, 15-MAY-2023 17:00-20:00 IDT • 10:00-13:00 EST
Theory Guest Lecture Practice
Inheritance, mutations,
screening.
Prof. Varda Shalev Group discussion:
If you could predict 3 genetic traits and 3
diseases, what would they be and who
would you screen for them (all the
population/part of it / symptomatic, and
so on.)
Details
In this capacity we will discuss the availability of genetic testing, what can be learned from
reading your own DNA, and what are the methods to ‘fix’ it.
Where can we take the technology to?
● Should we look into our DNA - ethical aspects
● What can go wrong
● Can we fix it
● Where are we heading
Session 4: DNA
When: Monday, 22-MAY-2023 17:00-20:00 IDT • 10:00-13:00 EST
Theory Guest Lecture
Machines and data generators Dr. Michal Rosen-Zvi
Details
● Where and when did sequencing begin
● Accumulating data and databases
● Mutations and rare diseases
● Somatic changes and cancer
● Cell-free DNA, advantages and limitations
9. DLC844066: The Future of Digital Medicine - Theory to Practice Page 9 of 15
Session 5: RNA and More
When: Monday, 29-MAY-2023 17:00-20:00 IDT • 10:00-13:00 EST
Theory Guest Lecture
More than DNA: types of data collection and
analysis
Prof. Avi Schroeder
Details
● Gene expression
● Micro-RNA expression
● Non-coding RNA
● Methylation, Chip-seq, transcription sites, etc.
Session 6: Technology
When: Monday, 5-JUN-2023 17:00-20:00 IDT • 10:00-13:00 EST
Theory Guest Lecture Practice
Sequencing, NGS,
microarrays
Dr. Christian Tidona Group discussion:
If you had a ubiquitous DNA-reading
technology, where would you take it
and what would you do with it?
Details
Here we will learn about the history of DNA sequencing from the first DNA read, in the 1960s,
to the first complete human-sequenced DNA in 2001. How has this technology advanced by
quantum leaps and what can we do with all the data collected?
What kind of analysis do we want to perform?
● Simple low throughput analysis
● High-throughput screening
● Adding complexity
● Advanced and beyond
10. DLC844066: The Future of Digital Medicine - Theory to Practice Page 10 of 15
Session 7: Research
When: Monday, 12-JUN-2023 17:00-20:00 IDT • 10:00-13:00 EST
Special Research Session Guest Lecture
Presentation of state-of-the-art medical
research in collaboration with Teva’s
National Bioinnovators Forum
Dr. Dana Bar-On
Details
Teva's National BioInnovators Forum is a unique program supporting and promoting the
translational aspects of biological therapies between academia and industry and advancing
entrepreneurship in the biomedical field.
The program awards Ph.D. students and post-doctoral fellows with scholarships on the basis
of excellence in studies and scientific research in the fields of brain disorders,
immunomodulation, protein engineering, drug delivery systems, mRNA-based therapy,
adverse reaction prediction, AI and big-data tools and approaches for all the above, and
more.
In the special Research session of the course, we will meet the 2022-2023 Bioinnovation
Program participants, who will share with us the foci and recent advances of their research - a
unique exposure to state-of-the-art medical research that would change the face of medicine
in the years to come.
11. DLC844066: The Future of Digital Medicine - Theory to Practice Page 11 of 15
Session 8: Bioinformatics and Systems
When: Monday, 19-JUN-2023 17:00-20:00 IDT • 10:00-13:00 EST
Theory Practice
Data and advanced analysis of systems Group discussion:
Plan an experiment that would help you to
deepen your understanding of a certain
disease? Which disease, and how would you
plan the experiment?
Details
Now that we know all about the cells, the DNA, and how to read it, we will learn how to parse,
organize, store and analyze the data. How can valuable information be retrieved from large
DNA experiments and what applications are there to human health?
● Collecting data
● Trying to make sense out of it
● Beware of overfitting
● Bioinformatics and beyond
● Integrating data into systems biology
● Alignment, assembly, variant calling
● Gene expression pathways and ontologies
● Nanopore sequencing
Session 9: Applications
When: Monday, 26-JUN-2023 17:00-20:00 IDT • 10:00-13:00 EST
Theory
How to bring data and findings to the market
Guest Lecture Guest Lecture
Mr. Eyal Toledano Ms. Gila Tolub
Details
● Clinical interpretation
● Applications and products
● Regulations and approvals
12. DLC844066: The Future of Digital Medicine - Theory to Practice Page 12 of 15
Session 10: Management
When: Monday, 03-JUL-2023 17:00-20:00 IDT • 10:00-13:00 EST
Theory Guest Lecture
Navigating the change Dr. Eyal Zimlichman
Practice
Group Discussion:
Take away lessons - where would you take the
technology?
Details
In this lesson we will see examples of DNA and RNA data analysis that has led to start-up
companies with promising horizons.
Bringing digital technology to the medical practice.
● Leaving the lab
● Looking for a market
● Building a product
● Doing good
● Making money
13. DLC844066: The Future of Digital Medicine - Theory to Practice Page 13 of 15
Participants of DigitalRosh courses say:
“The LLL model is the new standard that should now be everywhere, both for us as
individuals and in organizations, each in their own field. Everything is changing and
we have to learn constantly. Thank you so very much” Lee Betzer
More Details and Registration
Course language:
The program is delivered in English, as well as all the course materials.
Scope:
● Group and peer learning: 30 academic hours in online meetings, on Mondays,
15:00-18:00 UTC/ 16:00-19:00 CET/ 17:00-20:00 IDT/ 10:00-13:00 EST.
● Theory: Watching, reading, and self-learning for about 18 hours
● Practice: Watching, reading, and self-learning for about 18 hours
Tuition Fees:
“Early Bird” – until February 28, 2023: USD 1,200 (~NIS 4,060, IL VAT included)
Full tuition fee – until March 31, 2023: USD 1,800 (~NIS 6,090, IL VAT included)
Late registration fee (upon availability): USD 2,200 (~NIS 7,440, IL VAT included)
The tuition fee is payable via bank transfer or credit card.
If you wish to pay via bank transfer please contact Dr. Vladi Dvoyris, the course
manager, at vladi.dvoyris@digitalrosh.com
Registration is open until Saturday, April 15, 2023, subject to availability.
DigitalRosh membership:
The participants will receive a DigitalRosh PRO membership and enjoy the site and the
community services, among others:
● Full access to DigitalRosh Corpus, with over 1500 knowledge items: articles,
guides & tools, and case studies.
● Networking opportunities with DigitalRosh community members
● Invite to DigitalRosh LIVE webinar series and other community events.
Full information about our services is available at https://digitalrosh.com
What's next?
You are invited to register for the course at the registration page
Have questions? Wish to speak with the course manager? Fill in the interest form
or contact Dr. Vladi Dvoyris, the course manager: vladi.dvoyris@digitalrosh.com
14. DLC844066: The Future of Digital Medicine - Theory to Practice Page 14 of 15
Appendix 1: The World of Digital Medicine on DigitalRosh
A curated selection of knowledge items on Digital Medicine is available to course
participants on DigitalRosh.
15. DLC844066: The Future of Digital Medicine - Theory to Practice Page 15 of 15
Appendix 2: Testimonials of Previous Courses’ Participants
"The wide variety of participants is excellent. I liked the discussion groups and enjoyed
the new directions I encountered while working in a group. I made new friends with
whom I continued the professional conversation beyond the course time."
Karin Witzfeld, IDF
“This is an excellent course, delivered digitally. The lecturers were fantastic, the subject
is super interesting and relevant. Additionally, the platform made it great - lots of
additional content and easy to navigate. Thank you,
Yuval Sagron, Entrepreneur, Virgo.
“I learned many concepts that bring sense and order. I greatly appreciate learning how
you take a process and make it accessible. I was also amazed by the usage of Zoom:
how new worlds become accessible and how it enables learning for busy people."
Dorit Yaron, Head of IT, population authority, Interior Ministry
"There is generosity in DigitalRosh courses - the guest lectures, the availability of the
whole corpus, DigitalRosh LIVE webinars and the constant support”
Yossi Ani, GM, Madatech
"The wide variety of participants is excellent. I liked the discussion groups and enjoyed
the new directions I encountered while working in a group. I made new friends with
whom I continued the professional conversation beyond the course time."
Karin Witzfeld, IDF
"The digital community is not necessarily a community of technological people, because
digital affects all sectors and we see that there are people here from the field of
education, management, retail, health, etc. and in the end they all have a common
denominator - to make the digital revolution.”
Udi Kauf, Head of defense sector, EMT Technologies
"Throughout the course I found myself quite often telling my team insights I was inspired
by during learning. The mentors contribute a lot to the process. You have managed to
create a strong desire for continuity and there is so much more material to connect
with.”
Shoshi Becker, Bar Ilan University
“The course made it clear to me how to look at the process that my organization is going
through these days, and gave me tools that I brought up to our management.”
Amnon Vidan, Head of Operations and Resources, Clalit Innovation